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Abstract  
Pentose Phosphate Pathway (PPP) is a major glucose metabolism pathway which has a fundamen-
tal role in cancer growth and metastasis. Even though PPP blockade has been pointed out as a very 
promising strategy against cancer, effective anti-PPP agents are not still available in the clinical 
setting. Here, we demonstrate that the natural molecule polydatin inhibits glucose-6-phosphate 
dehydrogenase (G6PD), the key enzyme of PPP. Polydatin blocks G6PD causing accumulation of 
reactive oxygen species and strong increase of endoplasmic reticulum stress. These effects are fol-
lowed by cell cycle block in S phase, an about 50% of apoptosis, and 60% inhibition of invasion in 
vitro. Accordingly, in an orthotopic metastatic model of tongue cancer, 100 mg/kg polydatin in-
duced an about 30% tumor size reduction with an about 80% inhibition of lymph node metastases 
and 50% reduction of lymph node size (p< 0.005). Polydatin is not toxic in animals up to a dose of 
200 mg/kg and a phase II clinical trial shows that a is also well tolerated in humans (40 mg twice a 
day for 90 days). Thus, polydatin may be used as a reliable tool to limit human cancer growth and 
metastatic spread. 
 
 
Introduction 
 
The Pentose Phosphate Pathway (PPP) has recently been shown to have a crucial role in cancer 
cell growth by providing both nucleotide precursors, needed for proliferation, and NADPH used for 
both intracellular ROS detoxification and catabolic metabolism 1-5. The inhibition of PPP key en-
zymes, including glucose-6 phosphate dehydrogenase (G6PD), strongly affects cancer cell prolifer-
ation in vitro as well as in vivo 6,7. G6PD is upregulated in many human cancers and correlates with 
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poor prognosis 8-12 whereas cancer patients harboring G6PD mutation show longer survival and 
reduced metastases 13-15. Moreover, G6PD activity can be regulated by oncogenes such as 
PI3k/AKT, Ras, Src, mTORC1, or by oncosuppressors such as p53 and TAp73 4. Interestingly, the in-
hibition of G6PD may restore sensitivity of cancer cells to chemotherapy 16. Therefore, PPP inhibi-
tion has been proposed as an attractive therapeutic strategy against cancer 17. However, the inhi-
bition of G6PD in clinical settings is hampered by the lack of specific inhibitors. To our knowledge, 
the only G6PD inhibitor ever used in vivo is the dehydropiandrosterone (DHEA), an endogenous 
steroid hormone, which is produced by adrenal glands acting as a metabolic precursor of andro-
gen and estrogen. DHEA is rapidly converted into steroid hormones in vivo and its efficacy as an 
inhibitor of G6PD is under dispute 18.  
Polydatin (3,4',5-trihydroxystilbene-3-β-d-glucoside; trans-resveratrol 3-β-mono-D-glucoside; 
piceid) is a natural molecule found in Polygonum Cuspidatum and other plants. Polydatin is a glu-
coside of resveratrol and, together with other polyphenols, has been shown to have several bio-
logical effects, including the induction of apoptosis in carcinoma cells 19-22. Here, we have studied 
the effects of polydatin on G6PD activity, ROS levels, ER stress and programmed cell death, and its 
role in inhibiting cancer cell proliferation and invasion both in vitro and in vivo.  
 
 
Results 
 
Polydatin inhibits cancer cell proliferation and cell cycle progression 
We assessed the viability of head and neck squamous cell carcinoma (HNSCC) cell lines after poly-
datin treatments at different concentrations (from 2 to 100 µM at 24 or 48 h), by MTT assay. We 
found that polydatin reduced cell viability in a dose- and time-dependent manner at an EC50 of 22 
µM for 24 h and 17µM for 48 h, respectively (Fig. 1 A). Based on these data we have selected, for 
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all the subsequent experiments, concentrations of 10, 20 and 30 µM that represent the EC25, 
EC50 and EC75. To confirm the effects on cell viability, we performed an apoptosis assay based on 
Annexin V/PI staining (Fig. 1B and S1A). We observed a dose- and time-dependent reduction of 
cell viability and an increased apoptosis and necrosis of treated cells. Polydatin affect as well the 
cell cycle inducing a block in the S phase that reflected the ability of polydatin to inhibit cell prolif-
eration (Fig. 1C and Fig. S1B). These results demonstrate that polydatin reduces viability, increases 
apoptosis and prevents cell cycle progression of primary HNSCC cells. Similar results were ob-
tained on breast cancer MCF7 cell line (Fig. S2 D-F). 
 
Polydatin induces ER stress-driven cell death 
To understand the molecular mechanism leading to cell death we hypothesized that polydatin 
could cause Endoplasmic Reticulum (ER) stress, which in turn can lead to apoptosis. We performed 
an immunofluorescence staining (IF) using the vital dye ER-Tracker, which accumulate into ER. As a 
positive control, we used tunicamycin, a known inducer of ER stress. Following treatment with ei-
ther tunicamycin or different concentrations of polydatin we observed an increased fluorescence, 
which corresponds to an enlarged ER (Fig. 1D). Inositol-requiring enzyme 1 (IRE1) is an enzyme 
with intrinsic kinase and endoribonuclease activity that is activated during ER stress. After oli-
gomerization and auto-phosphorylation, IRE1 acts on X-box binding protein 1 (XBP1) mRNA and 
causes an unconventional alternative splicing that activates XBP1 transcription factor to upregu-
late ER chaperones. Clusters of oligomerization of phospho-IRE1 were observed in both polydatin 
and tunicamycin treated cells by both IF (Fig. 1E) and immunoblotting (Fig 1 F). Moreover, a signif-
icant increase of XBP1 mRNA and its spliced form (sXBP1 mRNA) was observed. This effect was 
dose- and time-dependent and began 4 h following treatment (Fig. 1F). Following ER stress, both 
IRE1 and PERK (Protein kinase RNA-like endoplasmic reticulum kinase) induce the transcription of 
CCAAT-enhancer-binding protein homologous protein (CHOP), which is involved in the activation 
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of apoptosis. As expected, the phosphorylated form of PERK and two of its downstream effectors 
p-eIF2α and ATF4 increased after polydatin treatment (Fig 1G). Finally CHOP transcript and protein 
also increased in response to polydatin treatment in a dose- and time-dependent manner as early 
as 2 h after treatment (Fig. 1F,1G). ER chaperons such as BiP and CRT increased after treatment 
too, while CNX did not show significant changes upon treatment. To understand whether ER stress 
was driving cell death, we showed that the block of IRE1 or PERK activation, by specific inhibitors 
or by knockdown, partially reverted polydatin-induced cytotoxicity (Fig. 2A). 
 
 
Polydatin inhibits G6PD and induces oxidative and ER stresses  
To additionally investigate the molecular mechanism of action of polydatin, we performed a mass 
spectrometry protein expression analysis of cell lysates from untreated and polydatin-treated cells 
(Fig. S2A and S2B) that was compared with one from tunicamycin-treated cells. As expected, the 
expression of proteins involved in ER stress was affected by tunicamycin treatment (Table S1). Pol-
ydatin-treated cells also showed a pattern of expression that was consistent with stress response 
and which overlapped that one of tunicamycin-treated cells. Among the proteins modulated by 
polydatin, we found a group of proteins belonging to the family of oxidoreductases and that were 
not altered in tunicamycin-treated cells (Fig. S2B and Table S1). Specifically, we found that seven 
oxidoreductases, including Isocitrate dehydrogenase 1 (IDH1), G6PD and 6-phosphogluconate-
dehydrogenase (6-PGD), were significantly upregulated in polydatin treated samples (24 h treat-
ment). G6PD and 6-PGD are both part of PPP and together with IDH1 are responsible for the pro-
duction of almost all the cytosolic NADPH, which is necessary for redox balance. Indeed, we found 
a significant reactive oxygen species (ROS) accumulation following polydatin treatment (Fig. 2B, 
S5). ROS plays a critical role in many cellular processes and can be produced in the cytosol and in 
several organelles including ER and mitochondria. To determine the role of ROS accumulation in 
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ER stress, we incubate the cells with the antioxidant N-acetylcysteine (NAC), prior to polydatin 
treatment.  Pre-treatments with NAC completely abrogated ER stress induced by polydatin, sug-
gesting a causative link between oxidative and ER stress (Fig. 2C).  
As G6PD is the PPP limiting enzyme, its inhibition would affect NADPH production, and results in 
redox imbalance.  Thus, we hypothesized that the biological effects observed could be a conse-
quence of G6PD block. Therefore, we performed a G6PD enzyme activity assay on carcinoma pro-
tein lysates as well as on purified G6PD. In both cases, polydatin inhibited G6PD activity in a con-
centration-dependent manner (Fig. 2D, S2C). This was paralleled by an increase of the 
NADP+/NADPH ratio in a time-dependent manner (Fig. 2E). These results suggest that polydatin 
inhibits G6PD causing an imbalance in NADP+/NADPH ratio that leads to an increase of oxidative 
stress. The capacity of tumor cells to control oxidative stress through NADPH production is directly 
correlated with their ability to migrate. Indeed, in vitro invasion assays confirmed that polydatin 
inhibited cancer cell invasion in a dose-dependent manner (Fig. 2F).  
 
 
 
G6PD overexpression counteracts polydatin anti-tumor effects  
To confirm that G6PD inhibition was functionally related to the biological effects induced by poly-
datin, we generated a G6PD overexpressing cell line (MCF7G6PD+) (Fig. S3A). MCF7G6PD+ were re-
sistant to polydatin treatment in both viability assay and apoptosis analyses. Indeed, 70 µM Poly-
datin at 24 h cause a 50% reduction in viability in mock cells vs 35% in MCF7G6PD+. Moreover, 35 
µM polydatin at 48 h caused 65% mortality in mock vs 40% in MCF7G6PD+ (Fig. S3B). Polydatin 
treatment caused a strong and significant increase of the S phase of cell cycle at 17.5 µM (16 ± 5% 
to 63 ± 10%), while it increased both S and G1 phase at the expense of G2/M at 35 and 70 μM in 
mock transfected cells at 48 h. Analysis of cell cycle at 48 h showed always an increase of S and 
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G2/M phases.  On the other hand, the MCF7G6PD+ cell cycle, was much less perturbed by polydatin 
that induced only a small increase of S phase at a concentration of 35 µM at 48 h (from 20 ± 5% to 
48 ± 6%) (Fig. S3C). MCF7G6PD+ cells were resistant to ER stress induced by polydatin as showed by 
ER-Tracker staining (Fig. S3D). On the other hand, Tunicamycin induced a strong ER stress in both 
mock and MCF7G6PD+ cells. This result suggests that MCF7G6PD+ are not resistant to ER stress in-
duced by mechanisms independent from redox imbalance. To further confirm this, we show that 
CHOP and spliced-XBP1 transcripts were significantly higher in polydatin-treated mock cells than 
MCF7G6PD+ (Fig. 3B).  The phosphorylation and clustering of IRE1 was strong and evident in mock 
cells but completely undetectable in MCF7G6PD+ (Fig. S3D). Analysis of redox status after polydatin 
treatment revealed an about two-fold increase of ROS accumulation in mock cells at concentration 
above 17,5 µM (Fig. S3D) but no effect in MCF7G6PD+. Again, invasion ability of MCF7G6PD+ was in the 
same way much less inhibited by polydatin treatment if compared to mock cells (Fig. S3E).  
 
 
Polydatin prevents lymph node metastases in an experimental orthotopic model of cancer 
Polydatin induced cancer cell death and blocked invasion in vitro.  Therefore, we developed an or-
thotopic metastatic model of oral cancer by injecting UMSCC103 in mice tongues, assessing the 
timing of tumor growth and lymph node metastases occurrence. Primary tumors were examined 
at the end of the experiment when mice were sacrificed while lymph node metastases were fol-
lowed using ultrasound imaging. Primary tumor growth was determined by weighting entire 
tongues and showed statistically significant differences between polydatin-treated and untreated 
mice (Fig. 4A). The reduction of primary tumors’ growth was ≤30%.  The squamous cell carcinoma 
nature of the implanted tumor was confirmed by an expert pathologist (Fig. 4A). Ultrasound imag-
ing and size determination of cervical lymph nodes revealed a much greater effect of polydatin on 
metastases (Fig. 4 C, D). In details, the average size of untreated mice lymph nodes was 5 ± 0.5 
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mm2 versus 3 ± 0.3 mm2 (p<0.005) for the treated ones.  These data were confirmed after mice 
sacrifice and when lymph nodes were removed, weighted and examined by a pathologist. We 
were able to identify and remove about 5/6 cervical lymph nodes per mouse. Indeed, the average 
weight of untreated mice was 6.2 ± 0.3 mg versus 2.9 ± 0.1 mg for the treated ones (p<0.005) (Fig. 
4E). All lymph nodes were then examined for metastases and we found that only two of the treat-
ed mice (out of 10) had lymph node metastases while 8 out of 10 were observed in untreated 
ones.  
 
G6PD Inhibition increase the effect of chemotherapy. 
 
PPP has been suggested to be involved in drug resistance in both solid tumors and leukemia. Two 
major work of Gregory et al and Catanzaro et al. describe an involvement of G6PD in the re-
sistance to cisplatin and tyrosine kinase inhibitor 16,23. For this reason, we performed analysis of 
synergism for the combination of cisplatin/polydatin and afatinib/polydatin. Both combinations 
were highly synergic at all the concentration used (Fig 4F,G; S4).  
 
 
Discussion 
In the present manuscript, we have studied the effect of polydatin on cancer cells elucidating its 
biochemical mechanism of action and biological effects. Based upon our results, we provide evi-
dence showing that polydatin induces a potent cancer cell growth inhibition paralleled by a strong 
reduction of invasive properties of cancer cells in vitro and in vivo. The latter effect was reported 
for the first time and represents a major goal of cancer research, as cancer metastases control is 
an unmet need in cancer treatment. We demonstrate that polydatin directly inhibits G6PD, the 
limiting enzyme of PPP, causing redox imbalance, which results in ER stress, cell cycle arrest and 
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apoptosis. To elucidate the molecular mechanism of polydatin, we performed a quantitative pro-
teomic analysis of lysates from polydatin-treated cells at multiple time points, and compared the 
protein expression profiles with tunicamycin-treated cells. This approach enabled the identifica-
tion of a group of enzymes that significantly increased following the treatment with polydatin but 
not with tunicamycin. The enzymes belonged to the family of oxidoreductases and among these, 
three enzymes drew our attention: IDH1, G6PD and 6PGD. These three enzymes are involved in 
glucose metabolism and account for the production of most of the NADPH. The latter has been 
proposed as rate limiting for cell proliferation 24-26. Moreover, NADPH has been demonstrated to 
be fundamental for cancer growth and metastases 27,28. Indeed, we found that polydatin inhibited 
G6PD in either a cell lysate or using the purified enzyme.  To demonstrate that the cytotoxic ef-
fects of polydatin were mediated by G6PD inhibition, we generated a cell line overexpressing 
G6PD. In these cells, treatment with polydatin resulted in a much lower effect if compared to con-
trol cells. This was observed for all the biological parameters we analyzed. G6PD inhibition blocks 
proliferation and reduces DNA synthesis 29, an effect similar to that one observed when cancer 
cells are treated with polydatin that inhibits cell cycle at the S phase 30. In addition, the accumula-
tion of cells in S phase of cell cycle at the expenses of G2/M is consistent with nucleotides short-
age 31. It has to be highlighted that, although polydatin has been used for more than 30 years, the 
molecular mechanism responsible for the effects reported have never been elucidated. We 
showed, for the first time, that the biological effects produced by polydatin treatment depend on 
G6PD inhibition and PPP block. This is, in our opinion, a pivotal finding, as specific G6PD or PPP in-
hibitors are not currently available in clinical setting. Indeed, although the PPP has been identified 
as a target for cancer therapy 4,7,9,17,24 and recently pointed out to be responsible for drug re-
sistance in humans by a relevant study of Gregory et al. 23, the lack of specific inhibitors hampers 
research and clinical application that aim to target this pathway. The widely used G6PD inhibitor 
DHEA is rapidly converted in vivo into other hormones which makes this drug not active 18. The in-
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hibitory effect recorded in some clinical trials seems to be more luckily produced by the interac-
tion between DHEA and estrogen receptors. Moreover, the results obtained with DHEA in vitro 
need to be interpreted very carefully due to potential biasing by the several biological effects of 
this hormone. Interestingly, the capacity of tumor cells to control oxidative stress through NADPH 
production is directly correlated with their ability to form metastases in vivo 32. Moreover, Rich-
ardson et al., used breast epithelial MCF10A cells (the parental and benign MCF10A, premalignant 
MCF10AT, and malignant MCF10CA1a) and showed that PPP flux increases with malignancy and 
correlates with tumor aggressiveness 33. Consistently, the PPP is associated with invasiveness and 
seems to play a crucial role during the metastatic process by protecting metastatic cells 5,34. There-
fore, our findings demonstrate that polydatin inhibits cancer cell invasion through PPP-dependent 
NADPH decrease. On the bases of these findings, we developed an orthotopic and metastatic 
model of oral cancer showing that polydatin strongly reduced both tumor growth and lymph node 
metastases. Interestingly, polydatin has previously been administered in different animal models 
to a dose up to 200 mg/kg with no reported major cardiovascular, hepatic, bone marrow and renal 
toxicities 35-37. Pharmacokinetic studies showed that polydatin is absorbed and distributed to tis-
sues if given intravenously or by oral administration 38. Phase II clinical trials have been performed 
using polydatin at 20-40 mg twice a day for a period as long as three months and none of those 
reported any major cardiovascular, hepatic, bone marrow and renal toxic effects 39,40. We showed 
that the combination of polydatin with either cisplatin or afatinib is strongly synergic in inducing 
cytotoxicity on cancer cells. These results strongly suggest the use of polydatin in clinical trials in 
combination with other anti-tumor agents in integrated anti-cancer strategies. 
In conclusion, we show that polydatin reduces tumor growth and strongly inhibits lymph node me-
tastases in oral cancer in vivo models with no toxicity. This effect has to be correlated with the di-
rect inhibition of G6PD, the limiting enzyme of the PPP. This causes an impairment of NADPH pro-
duction, causing ROS-mediated ER stress, apoptosis and invasion inhibition.  
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Methods 
Chemicals, Cell culture and in vitro treatment 
All chemicals were purchased from Sigma-Aldrich (St. Louis, USA) unless otherwise specified. 
Trans-polydatin, with a purity grade higher than 99%, was been supplied by Ghimas spa (Casalec-
chio, Bologna, Italy). Selective inhibitors of IRE1α (4μ8C) and PERK (GSK 2606414) were obtained 
from Tocris Bioscience (Bristol, United Kingdom). Afatinib (BIBW2992) was obtained from 
Boehringer Ingelheim (Milano, Italy). UMSCC103 (OSCC cell line) used in this study were estab-
lished at the University of Michigan under a protocol approved by the Institutional Review Board 
Office in accordance with the university's regulations and described here41. MCF7 cells were pur-
chased from ATCC. Cells were cultured in DMEM (Gibco, NY, USA) supplemented with 2 mM glu-
tamine, 100 IU/mL penicillin, 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA), and 10% heat-
inactivated fetal bovine serum (FBS) (Gibco, NY, USA) at 37°C in a humidified atmosphere under 
5% CO2. All cell lines were kept mycoplasma free, checking was performed every three months.  
 
Invasion Assay 
The invasion assays were performed using a BD BioCoat Matrigel Invasion Chamber and BD control 
inserts (Becton-Dickinson, USA). The cells, exposed for 24 h to DMEM alone and with different 
concentrations of polydatin, were re-suspended in serum-free DMEM and then added onto inserts 
with uncoated filters (control inserts) or onto inserts with Matrigel coated filters (invasion cham-
bers) at the density of 5×104 viable cells/insert. DMEM containing 10% FBS was used as the chem-
oattractant. Non-invading cells on the upper side of the membrane, after incubation for 18 h at 
37°C, 5% CO2, were removed with cotton swabs and the invading cells were fixed using methanol 
and stained with hematoxylin. Cells that invaded were counted at 200x magnification. Each assay 
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was performed in triplicate. Cells that invaded the Matrigel insert was compared to the number of 
cells that migrate in the control insert, calculating as percentage of invasion42. 
 
RNA isolation and qRT-PCR 
Total RNA was isolated by RNeasy Mini Kit (Qiagen) according to manufacturer's instructions, RNA 
was treated with DNase (Promega, Milan, Italy) to exclude DNA contamination and 1 μg total RNA 
reverse-transcribed using VILO SuperScript (Invitrogen, Monza, Italy). Gene expression assays were 
performed on a StepOne Thermocycler (Applied Biosystems, Monza, Italy) and the amplifications 
carried out using SYBR Green PCR Master Mix (Applied Biosystems, Monza, Italy). The reaction 
conditions were as follows: 95 °C for 15 min, followed by 40 cycles of three steps consisting of de-
naturation at 94 °C for 15 s, primer annealing at 60 °C for 30 s, and primer extension at 72 °C for 
30 s. A melting curve analysis was performed from 70 °C to 95 °C in 0.3 °C intervals. Each sample 
was performed in triplicate. GAPDH was used to normalize for differences in RNA input. qRT-PCR 
primer sequences are given in Supplementary Table 2. 
 
Glucose 6 Phosphate Dehydrogenase Assay and NADP+/NADPH Quantification 
G6PDH activity was measured by Glucose 6 Phosphate Dehydrogenase Assay Colorimetric Kit 
(Abcam, Cambridge, UK). UMSCC 103 cells untreated or treated with polydatin were homogenized 
in cold PBS, followed by centrifugation at 8000 x g for 10 min to remove insoluble materials. 
G6PDH activity was determined by analysis of G6PDH-dependent oxidation of glucose-6-phospate 
which leads to the conversion of a nearly colorless probe to an intensely colored product with an 
absorbance at 450 nm. All assays were performed at 37°C. NADP+/[NADPH ratios in cell lines 
treated with PD were measured according to the protocol of NADP+/[NADPH Quantification Kit 
(MAK038, Sigma). According to the NADPH standards, the concentration of NADPtotal or NADPH 
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can be expressed in pmole per 106 cells. The ratio of NADP+/[NADPH was calculated by ([NADPto-
tal] – [NADPH])/[NADPH]. 
 
Cell viability assay 
Cell viability was measured by the colorimetric 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Cells were seeded in 96-well plates at a density of 104 
cells per well, then they were treated with 100 μL of 1 mg/mL MTT (Sigma) in DMEM medium con-
taining 10% fetal bovine serum for 4 h at 37 °C. The medium was then replaced with 200 μL of 
DMSO and shaken for 15 min, then absorbance at 540 nm was measured using a microplate ELISA 
reader with DMSO used as the blank. To quantify the synergistic or antagonist effect of the drugs 
combinations, CompuSyn softwere was used43 . 
 
 
Immunofluorescence staining 
After 24 h treatment with PD at various concentrations, cells were washed in PBS and fixed with 
4% paraformaldehyde (PFA) solution and permeabilized with 0.1% TRITON -X/PBS solution, then 
was performed a blocking in 1% BSA for 1 hat RT. Cells were incubated with anti-pIRE (Abcam, 
Cambridge, UK) in PBS for 30 min. Secondary antibodies were added after a PBS wash in the same 
conditions. Cells were incubated in a 1:500 solution of 10 mg/mL Hoechst (Invitrogen) in PBS for 
10 min in the dark. To stain endoplasmic reticulum cells were incubated with 200 nM ER-Tracker 
Blue-White DPX in PBS solution for 20 min at 37°C. For positive control cells were exposed for 16 h 
to 5 μg/mL tunicamycin.  Images were collected under a fluorescence microscope (EVOS FL Cell 
Imaging System, Thermo Scientific, Rockford, USA).  
 
CellROX assay 
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Cells were plated on glass bottom 35-mm MatTek dishes and treated with PD for 24 h or 100 μM 
menadione for 1 h at 37°C. 50 μM N-acetyl cysteine was added menadione-treated wells. The cells 
were then stained with 5 μM CellROX green reagent by adding the probe to the complete media 
and incubating at 37°C for 30 min. The cells were then washed with PBS and then imaged on a flu-
orescence microscope EVOS FL Cell Imaging System (Thermo Scientific, Rockford, USA). N-acetyl 
cysteine treatment inhibited the fluorescent signal induced by menadione, confirming that the 
signal was specifically produced by ROS increase44,45. 
 
FACS analysis  
Apoptosis (Annexin V apoptosis detection kit, BD biosciences), CellROX assay (Thermo Fisher Sci-
entific, USA), were performed according to the manufacturer’s instructions. Cells were analysed 
with a FACSAria III (BD Biosciences, San Jose, CA) or a BD Accuri Cytometer (BD Biosciences, San 
Jose, CA). Data were analysed by FlowJo V10 software (FlowJo LLC, USA). For cell Cycle Analysis, 
cells were detached from the plates by trypsinization and then fixed with ice-cold 80% ethanol. 
The cells were centrifuged and then stained with a solution of 50 µg/mL propidium iodide and 80 
µg/mL RNase A for 60 min at 4°C in the dark. DNA content and cell cycle distribution were meas-
ured with a FACS ARIA III or BD Accuri Cytometer, data were analyzed using Mod-Fit software (Ver-
ity Software House, USA). 
 
 
G6PD overexpression 
p3-G6PD-t1 and negative control pCMV3-untagged-NCV (control) hygroycin-resistant plasmids 
were purchased from Sino Biological Inc. (Sino Biological, Beijing, China). MCF7 cells were stably 
transfected with Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA USA) according to 
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the manufacturer's instructions. Clones with upregulated expression of G6PD were selected with 
100 µg/mL Hygromycin. Clones were screened by Western blot. 
IRE1 and PERK downregulation 
UMSCC103 cells were transfected with siRNAs targeting IRE1 (SASI_Hs01_00194923, Sigma), PERK 
(SASI_Hs0100096844, Sigma)  or a control siRNA (SIC001, Sigma) using Lipofectamine 3000 (Ther-
mo Fisher Scientific, Waltham, MA USA) by following the manufacturer's instructions. 
 
Protein extraction and Western Blotting 
Cells were lysed in 1x RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 
50 mM Tris.Cl pH 7.5) plus 1% protease inhibitor cocktail, 1% PMSF(200mM) and 1% sodium or-
thovanadate (Santa Cruz Biotechnology, USA). Lysates were clarified by centrifugation at 8000 x g 
for 5 min at 4°C and equal amounts of protein were fractionated by SDS-PAGE and subsequently 
transferred onto nitrocellulose membrane, immunoblots were visualized using Supersignal® West 
Pico Chemiluminescent substrate (Thermo Scientific, Rockford, USA). Proteins were detected with 
anti-Glucose 6 Phosphate Dehydrogenase (Novus Biologicals, USA); Anti-PERK (phospho T981) 
(#1055, Elabscience, Huston, USA); Anti-PERK (#3667, Elabscience, Huston, USA); anti-IRE1 (phos-
pho S724) (ab48187, Abcam, Cambridge, UK); anti-IRE1 (ab ab37073, Abcam, Cambridge, UK); An-
ti-eIF2α (phosphor S51) (9721, Cell Signaling, USA); anti-α-Tubulin Antibody (#2144 Cell Signalling 
Technology, UK); Anti-Calreticulin (ab2907, Abcam, Cambrige, UK); Anti-Calnexin (ab22595, 
Abcam, Cambrige, UK); Anti-BiP (BD610978, BD Biosciences, San Jose, CA); Anti-ATF4 (sc-200, San-
ta Cruz, Dallas, USA); Anti-Chop (sc7351, Santa Cruz, Dallas, USA); Anti-XBP1 (ab198999, Abcam, 
Cambrige, UK) and  Anti-GAPDH (ab9485, Abcam, Cambridge, UK) were used for assessing loading. 
 
Mass Spectrometry  
Samples (~50 µg protein) were reduced, alkylated and prepared as previously described 46. Sam-
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ples (3 µL, ~ 5 µg protein digest) were directly injected by autosampler (Eksigent nanoLC 425 LC 
system) at 5µL/min onto a YMC Triart-C18 column (15 cm, 3 µm, 300 µm i.d.) using gradient elution 
(2–40% Mobile phase B, followed by wash at 80% B and re-equilibration) over either 73 (120 min 
run time) min (for spectral library construction using data/information dependent acquisition 
DDA/ IDA) or 43 min (60 min run time) for SWATH/DIA (Data Independent Acquisition) analysis. 
Mobile phases consisted of A: water containing 0.1% (v/v) formic acid; B: acetonitrile containing 
0.1% (v/v) formic acid. The LC system was hyphenated to a Sciex TripleTof 5600+ mass spectrome-
ter fitted with a Duospray source and 50 µm electrode suitable for microflow proteomic analysis.  
The IDA method was run with parameters of: CUR 25; GS1 15; GS2 0; ISVF 5500; TEM 0.  TOFMS 
mass range of 400-1250 m/z; accumulation time of 250 ms with product ion scans on the top 30 
ions before switching (dynamic exclusion for 20 s) with rolling collision energy selected.  Product 
ion accumulation time was set to 50 ms giving a cycle time of 1.8 s.  The SWATH method was run 
with the same source parameters as the IDA with a 50 ms TOFMS scan followed by 100 variable 
SWATH windows (optimised on an IDA datafile of the same samples) of 25 ms between 100-1500 
m/z giving a cycle time of 2.6 s. 
A spectral library for SWATH data extraction was constructed using the output from ProteinPilot 
5.0 (Sciex) searching against the Swissprot Human database (Jan 2015) with the addition of iRT 
peptides to the. fasta file, combining 8 IDA runs (pooled samples) and filtered and aligned to 
spiked in iRT peptides (Biognosys, Switzerland) using PeakView 2.1 (Sciex). SWATH data extraction, 
quantitation and fold change analysis were carried out using Sciex’s OneOmics cloud processing 
software suite incorporating processing methodology from47.  Proteins were considered as differ-
entially expressed if they had quantitative data on more than a single peptide, with a OneOmics 
confidence threshold of 70%. 
In vivo experiments  
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Twenty Foxn1nu nude male mice (6–8 weeks old) were purchased from the Harlan, Italy 
(Sanpietro al Natisone). The mice were maintained under pathogen-free conditions with food and 
water ad libitum, on 12 h/12 h day/night cycle, a temperature of 20 ± 2 °C, 10 mice per cage ran-
domized according to weight and tumor burden and divided in two treatment groups respectively; 
control vehicle (Ethanol 100%) and polydatin 100 mg/kg i.p. UMSCC 103 cells were trypsinized, 
centrifuged and then resuspended in serum-free medium. For implantation, tumor cells were or-
thotopically inoculated into the right lateral portion of the tongue of mice (1 × 106 cells per mouse) 
using a syringe with a 30 gauge disposable needle (BD Biosciences).  Animals were anesthetized 
with intraperitoneal injections of zolazepam, atropine and xilazine. From 10 days post injection, 
mice were treated three times a week with either control vehicle or polydatin 100 mg/kg via i.p. 
Tumor growth was assessed every three days, and cervical lymph node metastasis were evaluated 
with Ultrasound System Vevo 2100 (Visualsonics, Canada) at 10 and 20 days post cell injection. For 
each group the area of the cervical lymph-node was assessed with the Vevo 2100 commercial 
software.  At the end of the experiment (30 days of treatments), mice were sacrificed by 
CO2 inhalation, dissected, and the tongue and cervical lymph nodes weighed and photographed. 
The experimental protocols were in compliance with the European Community Council directive 
(86/609/EEC). 
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Figure legends 
 
Figure 1. Effects of polydatin treatment on UMSCC103.  
A) Viability assay measured by MTT (concentration range 0-70 µM) at 24 and 48 h post treatment. B) Analysis of apop-
tosis by Annexin V/PI assay at 24 and 48 h post-treatment (for original dot plots see Fig. S1A). C) Cell cycle analysis (for 
original histograms and analyses see Fig. S1B). D) IF with ER-Tracker 24 h post-treatment; tunicamycin is used as posi-
tive control. E) Immunoblot for phospho-IRE1, 24h post-treatment, Polydatin treatments 10-30 μM. IF for phospho-
IRE1, 24 h post-treatment; tunicamycin is used as positive control; red arrows represent phospho-IRE cluster. F) Quan-
titative real time PCR for CHOP and spliced XBP1. G) Immunoblot for UPR pathway and ER chaperons, 24h post-
treatment, Polydatin 20μM. * p<0.05. N=3, error bar = 95% confidence 
 
 
  21
Figure 2. Polydatin Inhibits G6PD causing redox imbalance, which leads to ER stress and cell 
death. 
Viability assay (MTT) of UMSCC103 treated with polydatin (20 µM) and 4μ8Χ (IRE inhibitor), GSK2606414 (PERK inhibi-
tor) or with siRNA for either IRE1 and PERK, 24h and 48h post-treatment. B) IF with CellROX (for oxidative stress de-
termination), 24 h post-treatment; (In fig S5: menadione is used as positive control; N-acetylcysteine (NAC) is used as 
ROS scavenger; quantitative assay). C) IF with ER-Tracker on UMSCC103 treated with polydatin in combination with 
NAC, 24 h post-treatment. D) G6PD enzymatic assay on UMSCC103 cell lysates (the same assay performed with puri-
fied enzyme is found in Fig. S2C). E) NADP+/NADPH ratio on polydatin-treated cells. F) Invasion assay of UMSCC103 
after polydatin treatment. *p<0.05, N=3, error bar = 95% confidence 
 
 
Figure 3.  Generation of G6PD overexpressing cell lines. Differences with mock transfection after 
polydatin treatment. 
A. Viability assay (MTT) in G6PD+ and mock-transfected cells following polydatin treatment. B) Quantitative real time 
PCR on G6PD+ and mock-transfected cells for CHOP and spliced XBP1 after polydatin treatment. C) IF with ER-Tracker 
on G6PD+ and mock-transfected cells after polydatin treatment. D) Flow cytometry of CellRox (oxidative stress deter-
mination) on G6PD+ and mock-transfected cells following polydatin treatment. E)  Invasion assay in G6PD+ and mock-
transfected cells. * p<0.05, N=3, error bar = 95% confidence. 
 
 
Figure 4. Analysis of tumor growth and lymph node invasion in an orthotopic xenograft model. 
A) H&E staining of orthotopic xenograft in the tongue; Bars, tongue weight of treated and untreated mice. B) H&E 
staining of lymph node metastases. C) Lymph node sonography and size determination on treated, untreated and con-
trol (no tumor) mice. Insets on the right, enlarged images. D) Plot of lymph node size determined by sonography. E) 
Lymph node weights of treated and untreated mice. F,G) analysis of combination index (CI) with compusin software 
for the combination polydatin/cisplatin and polydatin/afatinib. * p<0.05, N=3, error bar = 95% confidence. 
 
 
Fig. 5 Schematic representation of Polydatin action on cancer cells. 
 
 





